Skip to content

Earnings call

Tarsons Products Q4 FY26 earnings call: Tarsons expects improved operating leverage from ramping up its new facilities to aid operational performance from FY'27

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

Tarsons expects improved operating leverage from ramping up its new facilities to aid operational performance from FY'27. Tarsons' largest-ever capex program was intended to expand capacities and capabilities to support growth over the next 5 to 7 years; Tarsons believes the heavy investment phase is now largely behind it. Tarsons achieved its highest-ever quarterly revenue in Q4 FY'26, with revenue of INR121 crores, up 7.4% year-on-year; FY'26 revenue was INR426 crores, up 7.7% year-on-year. Tarsons grew approximately 16% quarter-on-quarter while the industry grew 3%; year-on-year, Tarsons grew 4.5% while the industry declined around 8%. Tarsons said its focus over the next 2 to 3 years is to ramp up capacity, grow scale and earn larger cash profits to deleverage; it would ideally not want debt to exceed 2x EBITDA and might look to raise money if debt remains significantly high, provided a significant opportunity arises and markets are favorable.

The numbers management gave

Results

  • Tarsons achieved its highest-ever quarterly revenue in Q4 FY'26, with revenue of INR121 crores, up 7.4% year-on-year; FY'26 revenue was INR426 crores, up 7.7% year-on-year.
    Show source
    Our revenue stood at INR121 crores, reflecting a year-on-year growth of 7.4%, while the revenue for FY'26 stood at INR426 crores, registering a growth of 7.7% year- on-year.
  • Tarsons standalone revenue in Q4 FY'26 was approximately INR97 crores versus INR93 crores in Q4 FY'25, up 4.4% year-on-year; domestic business grew 11.7%, while exports declined 13.4% primarily due to the Middle East crisis disrupting supply chains and shipment dispatch, as well as uncertainties surrounding U.S.; FY'26 revenue was INR332.9 crores, up 6% year-on-year.
    Show source
    On a stand-alone basis, our revenue for Q4 FY'26 stood at INR97 crores as compared to INR93 crores in Q4 FY'25, representing a 4.4% growth year -on-year.
  • Tarsons' export business declined 13.4% in Q4 FY'26, largely because Middle East geopolitical tensions and the warlike situation disrupted global supply chains and delayed shipments across international markets; container unavailability, elevated freight costs and uncertainty also contributed to the temporary export revenue decline.
    Show source
    Overall revenue growth, however, was impacted by a decline of 13.4% in the export business during Q4 FY'26, which was largely due to the ongoing geopolitical tensions and warlike situation in the Middle East.
  • Tarsons domestic revenue grew approximately 12% year-on-year in Q4 FY'26.
    Show source
    Despite these external challenges, our domestic business demonstrated strong resilience and continued to outperform, delivering approximately 12% ye ar-on-year growth in Q4 FY'26.
  • Tarsons standalone revenue grew 6% year-on-year in FY'26, with domestic business growing 7% and exports registering around 3%.
    Show source
    For the full year FY'26, stand-alone revenues grew by 6% year-on-year with domestic business growing by 7% and exports registering around 3%.
  • Tarsons' Q4 and FY'26 gross and EBITDA margins declined because raw material prices increased significantly during February and March amid commodity price movements and global supply chain disruptions; gross margin contracted during the quarter.
    Show source
    While the margins for Q4 and FY'26, both the gross margin and the EBITDA margin witnessed some decline due to a significant increase in the raw material prices during February and March, driven by commodity price movements and global supply chain disruptions.
Show 17 more statements

Results

  • Tarsons' gross margins remained around 71% to 72% during FY'26, but were affected over the past couple of months by a considerable raw material cost spike driven by global supply chain disruptions following the onset of the Middle East conflict.
    Show source
    While gross margins remain relatively stable at around 71% to 72% during FY'26, the gross margin has been impacted over the past couple of months by a considerable spike in raw material costs, driven by disruptions in global supply chains following the onset of the Middle East conflict.
  • Tarsons' PAT for Q4 and FY'26 was affected by higher depreciation and interest costs following commissioning of the new capex, and FY'27 PAT is likely to remain relatively moderate.
    Show source
    PAT for both Q4 and FY'26 was impacted Page 3 of 19 Tarsons Products Limited May 25, 2026 by higher depreciation and interest costs following the commissioning of the new capex.
  • Tarsons consolidated cash PAT was INR112 crores in FY'26 versus INR92 crores in FY'25, representing growth of 21.5%.
    Show source
    On a consolidated basis, cash PAT for FY'26 stood at INR112 crores compared to INR92 crores in FY'25, representing a strong growth of 21.5%.
  • Tarsons standalone gross margin was 58.5% in Q4 FY'26, mainly affected by high raw material costs arising from commodity price volatility; FY'26 gross margin remained around 71%.
    Show source
    Gross margin for the standalone business in Q4 FY '26 stood at 58.5% impacted mainly by high raw material costs arising from volatility in commodity prices.
  • Tarsons EBITDA was INR32.6 crores in Q4 FY'26 and INR110.1 crores in FY'26; EBITDA margins were affected by high commissioning and operational expenses related to the Amta and Panchla facilities.
    Show source
    EBITDA for Q4 FY '26 and FY'26 stood at INR32.6 crores and INR110.1 crores, respectively.
  • Tarsons PAT was INR5.5 crores in Q4 FY'26 and INR22.7 crores in FY'26, with profitability affected by higher depreciation and interest expenses associated with the new capex.
    Show source
    PAT for Q4 FY '26 stood at INR5.5 crores while FY'26 PAT stood at INR22.7 crores, profitability was impacted by higher depreciation and interest expenses associated with the new capex.
  • Approximately INR49 crores of Tarsons' total depreciation of INR87 crores in FY'26 related to the Panchla and Amta facilities.
    Show source
    Approximately INR49 crores out of the total depreciation of INR87 crores in FY'26 was for the Panchla and Amta facilities.
  • Tarsons adjusted cash PAT was INR31.9 crores in Q4 FY'26 and INR111.1 crores in FY'26, up 15% year-on-year.
    Show source
    Adjusted cash PAT for Q4 FY'26 stood at INR31.9 crores while FY'26 adjusted cash PAT stood at INR111.1 crores, reflecting a growth of 15% year-on-year.
  • Tarsons consolidated revenue was INR120.9 crores in Q4 FY'26, up 7.3% year-on-year, and INR422.5 crores in FY'26, up 7.7% year-on-year.
    Show source
    On a conservative performance basis, consolidated revenue for Q4 FY'26 stood at INR120.9 crores, registering a growth of 7.3% year-on-year, while FY'26 consol revenue stood at INR422.5 crores, reflecting a growth of 7.7% year-over-year.
  • Tarsons consolidated EBITDA was approximately INR34.3 crores in Q4 FY'26, with an EBITDA margin of 28.3%, and FY'26 consolidated EBITDA was INR117.9 crores.
    Show source
    EBITDA for Q4 FY'26 stood at approximately INR34.3 crores while an EBITDA margin of 28.3%.
  • Tarsons adjusted cash PAT was INR33 crores in Q4 FY'26, up 9.3% year-on-year, and INR112 crores in FY'26, up 21.4% year-on-year.
    Show source
    Adjusted cash PAT for Q4 FY'26 stood at INR33 crores, reflecting a growth of 9.3% year-on-year while FY'26 adjusted cash PAT stood at INR112 crores, representing a strong growth of 21.4% year-on-year.
  • Tarsons consolidated cash flow from operations improved to INR118 crores in FY'26 from INR114 crores despite lower profitability.
    Show source
    At a consol level, we have marginally improved our cash flow from operations to INR118 crores compared to INR114 crores despite lower profitability in FY'26.
  • Tarsons said total purchases for the year are about to be INR15 crores to INR20 crores, so an INR14 crores increase in traded goods was not possible; the increase was INR1.4 million.
    Show source
    I think INR1.4 million is there, and you have made it INR14 crores.
  • Tarsons' EBITDA margins were affected by higher operating expenses related to its new plants, while the corresponding revenue contribution is expected to build gradually over the coming years.
    Show source
    EBITDA margins were also impacted by higher operating expenses related to our new plants should now become operational, while the corresponding revenue contribution is expected to build up gradually over the coming years.
  • At the consolidated level, only Nerbe was included, and Nerbe had no major depreciation except for some intangibles.
    Show source
    Santosh Agarwal: It's on a standalone level at a consol level, only Nerbe got included and Nerbe has no major depreciation, except some intangibles are there.
  • Tarsons PAT continues to be impacted by accelerated depreciation and interest cost associated with the new facilities.
    Show source
    PAT for both Q4 and FY'26 was impacted Page 3 of 19 Tarsons Products Limited May 25, 2026 by higher depreciation and interest costs following the commissioning of the new capex.

Money and capital

  • Tarsons said its focus over the next 2 to 3 years is to ramp up capacity, grow scale and earn larger cash profits to deleverage; it would ideally not want debt to exceed 2x EBITDA and might look to raise money if debt remains significantly high, provided a significant opportunity arises and markets are favorable.
    Show source
    Aryan Sehgal: See, we would definitely it would be to deleverage, reduce the debt on our books and I would ideally in a situation -- in an ideal situation, not want debt to increase more than 2x our EBITDA.

What it expects ahead

What management expects

  • Tarsons expects improved operating leverage from ramping up its new facilities to aid operational performance from FY'27.
    Show source
    At the same time, we expect improved operating leverage from ramping up the new facilities to aid the operational performance from FY'27.
  • Tarsons expects higher depreciation in FY '27 as INR158 crores of CWIP on its balance sheet will move to the main asset segment in FY'27, resulting in additional depreciation.
    Show source
    So, we expect a higher depreciation in FY '27.
  • Tarsons expects depreciation of INR105 crores to INR110 crores in fiscal '27, which management said would be its peak; the depreciation rate will remain the same because Tarsons follows the written down value method.
    Show source
    Only thing is that the depreciation amount will be in the range of INR105 crores to INR110 crores.
  • Tarsons expects its cell culture business to ramp up gradually, with a slower launch as customers become accustomed to the product, conduct tests and trials, and onboard Tarsons as a vendor; it expects significant momentum in years 2, 3 and 4, with significant scale-up starting in year 2 if the product meets expectations and is well accepted by customers.
    Show source
    But I think starting from year 2, we should see significant scale up if the product meets up to its expectations and is well accepted by the customer base.
  • Tarsons expects cell culture momentum to start towards the end of fiscal '27 or the beginning of fiscal '28; most product lines were launched towards Q4 of last year, and customers would initially use Tarsons as one of their vendors while assessing its reliability.
    Show source
    It should be towards the end of fiscal '27 -- fiscal -- beginning of fiscal '28, we should start seeing a lot of momentum because we've launched this product.
  • Tarsons expects the stabilizing Indian market to create an opportunity to gain more market share in India and expects good international growth over the next 3 to 4 years, while cautioning that geopolitical conditions could cause short- or mid-term setbacks.
    Show source
    But internationally, we are very, very bullish on good growth moving forward over the next 3 to 4 years.
Show 15 more statements

What management expects

  • Tarsons has focused on the U.S. and Europe and is looking to strengthen its presence in Asia and Latin America; it expects good growth from Asia and Latin America over the next 2 to 3 years, while a significant portion of its business will continue to come from the U.S. and Europe.
    Show source
    So, I think we will look at good growth coming in from Asia as well as Latin America over the next 2 to 3 years.
  • Tarsons expects good, stable growth from the domestic market over the next 2 to 3 years, primarily because of its position and base in that market.
    Show source
    So, what we expect is we expect good growth from the domestic market, strong stable growth from the domestic market over the next 2 to 3 years, primarily because of our position and our base in the domestic market.
  • Tarsons said international growth may not be homogeneous over the next 3 to 4 years, depending on geopolitical situations, economic tariff situations and the speed at which it can convert contracts; some years could see strong growth when it wins contracts and ODM businesses.
    Show source
    And so we could -- depending on geopolitical situations, economic tariff situations and everything being in order being in place, the speed at which we could convert contracts, the growth may not be very homogeneous over the next 3, 4 years, but there could be some strong years of growth when we win contracts and win ODM businesses.
  • Tarsons' consolidated depreciation is about to be INR85 crores to INR89 crores this year, with another INR25 crores to INR30 crores of depreciation in the next year, bringing it to about INR110 crores, plus some intangible depreciation and amortization at the consolidated level.
    Show source
    So, it will come to about INR110 crores, right.
  • Tarsons does not expect accounting losses and expects PAT to be in the range of a single-digit number, with EBITDA of about 33% to 34%, PBT of 9% to 10% and PAT of 4% to 5%; depreciation at the standalone level will not repeat at more than INR110 crores.
    Show source
    Of course, we expect PAT to be in the range of single-digit number, but it will not be losses so far, the way things are going on because we are making EBITDA of about to be 33%, 34% and then PBT is also 9% to 10% PBT is there and then 4% to 5% of PAT is also there.
  • Tarsons expects to enter most customer accounts, validate its product, become one of their vendors and build the repeatability and reliability customers expect this year; it expects improvement and annual scale-up starting in year 2, significant scale-up through about year 4 or 5, and stable growth thereafter.
    Show source
    And years starting from year 2, I think we would start seeing some improvements and then scale up every year, there would be significant scale up till probably year 4 or 5 where we reach certain amount of stability where there would be stable growth moving forward for these lines.
  • Tarsons expects initial benefits from its expanded capacities to start reflecting from the current financial year through higher volumes, improved product availability and incremental revenue contribution, while full utilization and ramp-up will take some time.
    Show source
    While the full utilization and ramp-up of these capacities will take some time, we expect the initial benefits to start reflecting from the current financial year itself through higher volumes, improved product availability and incremental revenue contribution.
  • Tarsons expects costs related to its Amta and Panchla facilities to stabilize and margins to improve as utilization ramps up over the coming years.
    Show source
    We expect these costs to stabilize and margins to improve as utilization ramp up over the coming years.
  • Tarsons expects its cell culture capacity to be filled by a mix of international and domestic customers, as domestic customers alone will not be able to fill it.
    Show source
    So, it definitely will have to be a mix of international and domestic.
  • Tarsons expects international growth percentages to be significantly higher than domestic growth percentages because the international opportunity is much larger, despite a lower base.
    Show source
    And internationally, I think the growth numbers could be much higher, significantly higher than domestic the growth percentages because although the base is lower than international domestic market, but still, I think the quantum of opportunity is much higher internationally.
  • Tarsons expects Q1 margins to be in similar regions to Q4, not worse.
    Show source
    Aryan Sehgal: It shouldn't be worse, but should be in similar regions.
  • Tarsons expects operating leverage as revenues scale up to support and improve overall EBITDA margins going forward. Replaced by a later filing.
    Show source
    As revenues scale up, we expect operating leverage to play out, supporting and improving our overall EBITDA margins going forward.
  • Tarsons expects its capacity investments to become a key driver of growth and operating leverage over the medium term. Replaced by a later filing.
    Show source
    Over the medium term, these investments are expected to become a key driver of growth and operating leverage for the company.
  • Tarsons expects stronger revenue growth as it expands its presence across domestic and international markets with an expanded product portfolio, which it expects to translate subsequently into improved profitability. Replaced by a later filing.
    Show source
    As we deepen our presence across domestic and international markets with an expanded product portfolio, we expect stronger revenue growth, which will subsequently translate into improved profitability.
  • Tarsons said it would find ways to maintain pricing and would need better conditions for uninterrupted and stronger growth in international markets. Replaced by a later filing.
    Show source
    But we would need better conditions for uninterrupted growth and stronger growth in international market.

What it is building and selling

Projects and capacity

  • Tarsons' largest-ever capex program was intended to expand capacities and capabilities to support growth over the next 5 to 7 years; Tarsons believes the heavy investment phase is now largely behind it.
    Show source
    During this period, the company was also undertaking its largest ever capex program aimed at significantly expanding capacities and capabilities to support growth over the next 5 to 7 years.
  • Tarsons has no additional capex plan for fiscal '27 and '28 beyond completing pending capex and CWIP; it expects some maintenance and required commercially viable capex, but no major capex.
    Show source
    Santosh Agarwal: There is no additional capex plan.
  • Tarsons has started pilot production on a few cell culture lines and will start pilot production on a few more in this quarter; it expects all lines to be ready to produce and supply samples in the next 2 or 3 months.
    Show source
    So hopefully, in the next 2 or 3 months, we should have all our lines up and ready and producing and supplying samples.
  • Tarsons has commissioned and made operational a substantial portion of its capex program; operations have commenced across bioprocess product lines, expanded liquid handling manufacturing capacities and selected cell culture product lines, while trial runs are underway for certain remaining product lines and facilities.
    Show source
    Past few quarters, we have commenced operations across several strategic product categories, including our bioprocess product lines, expanding liquid handling manufacturing capacities and selected product lines within the cell culture segment.
  • Tarsons expects its entire capex program to be fully commissioned during the first half of the current financial year.
    Show source
    We expect the entire capex program to be fully commissioned during the first half of the current financial year.
  • Tarsons said the ramp-up of bioprocess containers was going well, with bottles being produced. Replaced by a later filing.
    Show source
    The ramp-up is going well for the bioprocess containers, what we are producing the bottles.
Show 16 more statements

Demand and pricing

  • Tarsons grew approximately 16% quarter-on-quarter while the industry grew 3%; year-on-year, Tarsons grew 4.5% while the industry declined around 8%.
    Show source
    On a quarter-on-quarter basis, the industry recorded a modest growth of 3%, whereas Tarsons delivered a significantly strong growth of approximately 16%.
  • Tarsons observed some easing of supply chain-related issues over the past 2 weeks, and customer inquiries and order pipelines that had been subdued over the prior couple of months were gradually reviving.
    Show source
    In terms of recent developments, we have observed some easing of supply chain-related issues over the past 2 weeks.
  • Tarsons said its product portfolio had grown and that the Indian market had been pretty favorable over the last 6 to 7 months, supporting its growth momentum.
    Show source
    The situation in the market was pretty favorable over the last 6 to 7 months in India, and we grow on Page 8 of 19 Tarsons Products Limited May 25, 2026 that momentum.
  • Tarsons said Chinese competition is fierce in the U.S., Europe, Asia and Latin America, and that Chinese manufacturers have a 15-year lead over Indian manufacturers in laboratory consumables.
    Show source
    Chinese competition is fierce, both in the U.S. as well as Europe as well as other parts of the world, including Asia, Latin America and so on.
  • India exports approximately INR250 crores to INR275 crores of laboratory consumables into the U.S. between all companies, including Tarsons, while China exports more than INR275 crores a month into the U.S.; Chinese manufacturers have a limited and small presence in the Indian market but are very strong globally.
    Show source
    Aryan Sehgal: India exports approximately INR250 crores to INR275 crores of laboratory consumables into the U.S. between all companies, including Tarsons, just in the lab consumable space.
  • Tarsons has gradually started increasing prices because raw material prices have increased by 60% or 70%, but it may not be able to pass the entire cost increase to customers and may have to share some of it in the short term; Tarsons does not expect the situation to be permanent.
    Show source
    Aryan Sehgal: So, we are looking to gradually increase pricing because at 60% or 70% raw material price hikes, it is a large cost increase, and we would not be able to support such a large cost increase by absorbing it.
  • Tarsons said a 60% to 70% increase in material margin could move gross margin from 70% to 58% or 57%, which may look healthy but may not be sustainable in the long term.
    Show source
    So, while a 60%, 70% increase in material margin might just affect our gross margin by from 70%, it might take it to 58% or 57% and might look healthy, it may not be sustainable in the long term.
  • Tarsons is increasing prices product-line by product-line based on raw material increases and what it can achieve from customers, but is unsure how long the price increase will last and is in a wait-and-watch mode; its price-book process is generally yearly because changing the books every quarter or every 2 or 3 months would affect credibility and distributors' ability to stock correctly.
    Show source
    So hence, we are still in a wait-and-watch mode, and we are increasing as and when all the product lines based on how the raw materials have increased and what we can achieve from the customer.
  • Tarsons said a non-standard price increase of 30% or 40% could create a strong opportunity for other players to enter or gain market share; if raw material price increases become permanent and apply to everybody, Tarsons expects gradual pricing changes across the industry over the medium or short to medium term, while a short-term phenomenon lasting 3 or 4 months could be absorbed by industry players seeking market share.
    Show source
    However, if this becomes a permanent phenomenon and is valid to everybody, then over a medium term or short to medium term, we will see gradual changes in everybody's pricing.
  • Tarsons faces price competition in international markets from domestic Indian exporters and Chinese players.
    Show source
    There is a lot of price competition from domestic players in India exporting as well as from Chinese players.
  • Tarsons selects international customer segments and products where it can maximize value while delivering quality, and says it cannot win every customer or contract but has room for the value it delivers internationally.
    Show source
    And Tarsons looks at whatever its strengths are in terms of the products where it has an and where how we can be able to maximize our value while delivering quality.
  • Tarsons started gradually increasing prices in April of this fiscal year, assessing price changes product by product rather than across the entire price list; it said distributors would be cautious about holding large inventories at higher prices because the price increase is temporary.
    Show source
    So, we have gradually started in this fiscal year, which is April.
  • Tarsons said demand today is good but not significantly higher or unprecedentedly high as it was during COVID, so it cannot expect a COVID-like situation.
    Show source
    So, we cannot expect a situation like COVID today.
  • Tarsons said supply is constrained, but demand is not like it was during COVID and there is no comparison between COVID demand and today's demand.
    Show source
    Aryan Sehgal: Supply is constrained, but demand is not like the way it was in COVID.
  • Tarsons said U.S. buyers put pressure on the company because they know the rupee depreciates against the dollar but do not fully understand inflationary pressures and year-over-year cost increases in India, which differ from those in the U.S. or Europe.
    Show source
    So most of the times, we have pressures from our buyers in the U.S. because they are well aware of where the currency has depreciated over the last 10 or 15 years, the Indian currency, but not having complete information and understanding about the inflationary pressures in India and what sort of price increments or cost increments the company faces year-over-year, which is not similar to a standard scenario in the U.S. or in Europe.

Deals and partners

  • After completing its capacity expansions, Tarsons will serve many products from India for Nerbe, where financially viable.
    Show source
    Aryan Sehgal: We will after laying down all the capacity expansions what we have, we will be serving a lot of products from India for Nerbe.

Risks, rules and outside factors

Outside factors

  • Tarsons' FY'26 export performance was affected by tariff-related uncertainties, seasonally weaker Q3 demand during the international holiday period, and geopolitical disruptions in Q4.
    Show source
    Export performance during the year was impacted by multiple external factors, including tariff- related uncertainties during FY '26, seasonally weaker demand in Q3 due to the holiday period in international markets and geopolitical disruptions witnessed in Q4.
  • Tarsons said rupee depreciation over the last 6, 7 months, geopolitical transport-route problems and higher freight costs make imports into India more complicated and expensive; these factors favor producers in India, for whom raw material is the only imported cost component affected by rupee depreciation and the other cost components are local.
    Show source
    So , all these things always play favorably to make in India producers, not only Tarsons, but anybody else who produces in India because for us, the only component which is being imported where we are paying the higher price for the rupee depreciation is the raw material.
  • Tarsons purchases about INR70 crores to INR80 crores worth of raw material across 20, 30 or 40 different grades of polypropylene, HDP, polycarbonate and polystyrene from different vendors in the Middle East and Europe.
    Show source
    Page 15 of 19 Tarsons Products Limited May 25, 2026 Here, we are buying 20, 30, 40 different grades across different polypropylene, HDP, polycarbonate, polystyrene and we have a purchase of about INR70 crores, INR80 crores worth of raw material, which for the raw materials and spread across different vendors in the Middle East and Europe.
  • A particular raw material supplier supplies Tarsons INR6 crores, INR7 crores or INR8 crores of raw material a year, which Tarsons said is not significant or material to the supplier.
    Show source
    So, for any particular raw material supplier supplying to Tarsons worth INR6 crores, INR7 crores or INR8 crores of raw material a year is nothing significant or nothing material.
  • Tarsons said raw material suppliers based in the U.S. supplying U.S. manufacturers had not experienced as strong a price impact as suppliers and manufacturers in Asia, including China and India; U.S. cost pressures were inflation-related, not raw-material-linked.
    Show source
    And a lot of raw material suppliers based in the U.S. supplying to U.S. manufacturers, the price impact hasn't been as strong as what it has been here in towards Asia, towards China, India, manufacturers have been impacted much more severely as compared to the U.S. and Europe.
  • Tarsons said raw material supply and availability are industry-wide issues, and that it needs higher inventory levels, more stock and stronger supply chain systems to navigate the crisis.
    Show source
    But raw material availability is a reality at this point of time, raw material supply issues, and it's throughout the industry.
Show 1 more statement

Rules and policy

  • Tarsons said duties on Chinese and Indian products in the U.S. are very similar, while in Europe the India-EU FTA trade deal, if it comes into effect, might give Tarsons a benefit of about certain percentage points compared with Chinese products.
    Show source
    But in Europe, we had similar duties, but with the India, EU FTA trade deal, if it comes into effect, it is not yet into effect, we might have a benefit of about certain percentage points between us and the Chinese.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Rushabh Shah: There might be like in the export market, there might be some companies with a higher low-cost contract manufacturing with a higher reputation in the international markets. So how does like when Tarson approach a customer in the export market, so how does Tarson manage the response from the customers. So when you say they have a low-cost manufacturing and better branded than Tarson product in the international market. So how do you crack the customer in the international market?

    Answer, aryan sehgal

    Aryan Sehgal: No, I think it depends on the customer segments, what we are looking at. There is the market internationally is quite large and is available to wide range of companies selling in the international market. So, we do receive a lot of price competition. There is a lot of price competition from domestic players in India exporting as well as from Chinese players. And Tarsons looks at whatever its strengths are in terms of the products where it has an and where how we can be able to maximize our value while delivering quality. But we cannot win every customer and have every contract in place. We lose some contracts and win some contracts, but there's enough space and room for the kind of value we deliver, internationally.

  2. Question

    Rushabh Shah: Sir, my second question is on our domestic contract has been our decade-long exclusive agreements with the scientific distributors across India. So however, the unlisted players like Abdos and Accumax are aggressively expanding their product portfolio and offering highly competitive terms. So, are you seeing instances where our legacy distributors are onboarding these competitors for a low-priced product lines?

    Answer, aryan sehgal

    Aryan Sehgal: No. Most of the companies operating in the lab consumable space in India have their own channel, and that is beneficial for all companies involved, large, big, small, medium-sized companies because just like Tarsons would not like to share distribution partners with smaller medium players or even larger multinational players. Similarly, the smaller players would also try and appoint distributors who are exclusive to them and who are putting all their marketing efforts in the promotion and sale of their products.

    Answer, santosh agarwal

    So that will continue. And still in our balance sheet, INR158 crores of CWIP is there, that will get moved to main asset segment in FY'27 and additional depreciation will come from that as well. So, we expect a higher depreciation in FY '27.

  3. Question

    Avnish Tiwari: Right. But do you have some number like where it can go, your depreciation rate in fiscal '27?

    Answer, santosh agarwal

    Santosh Agarwal: The rate will be the same because we are following the written down value method. Only thing is that the depreciation amount will be in the range of INR105 crores to INR110 crores. That will be the peak for us.

  4. Question

    Avnish Tiwari: Okay. And what's the capex plan for fiscal '27 and '28, if you have?

    Answer, santosh agarwal

    Santosh Agarwal: There is no additional capex plan. Whatever capex is pending and whatever CWIP is there, we are just completing that. Apart from that, some maintenance and some required commercial viable capex will be there. Otherwise, no major capex.

  5. Question

    Avnish Tiwari: Business question I have on the cell culture. How do you expect the ramp-up in that business, let's say, this year, next year?

    Answer, aryan sehgal

    Aryan Sehgal: So, we expect cell culture to gradually ramp up. We would expect slower ramp-ups as we've commercially launched certain cell culture lines in the market over the last 2 to 3 months. So, we expect a slower launch as people get accustomed to the product, do their respective test and trials and onboard us as one of their vendors. And I think we should see some significant momentum towards year 2 and moving forward, year 2, 3 and 4 should be able to really help us scale up the volumes till we reach a sizable market size where we could have normalized growth levels. But I think starting from year 2, we should see significant scale up if the product meets up to its expectations and is well accepted by the customer base.

  6. Question

    Avnish Tiwari: The year 2 in this case would be fiscal '28.

    Answer, aryan sehgal

    Aryan Sehgal: Yes. It should be towards the end of fiscal '27 -- fiscal -- beginning of fiscal '28, we should start seeing a lot of momentum because we've launched this product. Most of the lines of the product we've launched towards Q4 of last year. So, it's been about 2 to 3 months. So, we expect the first Page 7 of 19 Tarsons Products Limited May 25, 2026 year where first year, where people generally don't in a product like cell culture, they would not just jump into conclusions and give you the entire volume. They would use you as one of the vendors and see how reliable we are in this. But the advantage that we have is that we know the company, they know the brand and you know the reputation which comes out from the products from Tarsons.

  7. Question

    Avnish Tiwari: And these are domestic, who are your customers? And typically, do you need that a lot of customers or fewer customers will fill up your capacity, assuming you start ramping up in year 2 and year 3?

    Answer, aryan sehgal

    Aryan Sehgal: No, I think it will be a mix of international and domestic. The kind of capacities what we have will not be able to be fulfilled just by domestic customers. So, it definitely will have to be a mix of international and domestic.

  8. Question

    Avnish Tiwari: And apart from the cell culture piece, how you expect the growth momentum in fiscal '27? Like where do you see each line of the business moving?

    Answer, aryan sehgal

    Aryan Sehgal: No, I think cell culture is just used as a single term because we've used it as a very broad term, but there are actually a lot of product lines for the bioprocess, biopharma, cell culture production market. And there are some significant capacity expansions in certain product lines what we already sell. I think the Indian market stabilizing puts us in a very good position to acquire more market share from the Indian market as well as the expansion in international markets, considering the world geopolitical situation globally remains stable. But internationally, we are very, very bullish on good growth moving forward over the next 3 to 4 years. But we are cautious that there could be certain blips in the midterm or the short term because of the geopolitical environment. But overall, strategy-wise, international market remains a robust opportunity for Tarsons. Avnish Tiwari: Are you serving something for Nerbe from India or you can after capacity expansion?

    Answer, aryan sehgal

    Aryan Sehgal: We will after laying down all the capacity expansions what we have, we will be serving a lot of products from India for Nerbe. Whatever is financially viable, of course, yes.

  9. Question

    Avnish Tiwari: Right. And on the Indian domestic side, what has changed lately, which has made growth rate pick up?

    Answer, aryan sehgal

    Aryan Sehgal: Of course, our product portfolio has grown. And I think the market is easing out a bit. The situation in the market was pretty favorable over the last 6 to 7 months in India, and we grow on Page 8 of 19 Tarsons Products Limited May 25, 2026 that momentum. I believe that whenever the market will be favorable, Tarsons will always have the best opportunity for growth, the way we positioned ourselves with the customer base as well as with the distribution network.

    Answer, aryan sehgal

    Aryan Sehgal: I would not be able to answer that clearly because at this point of time, we have a significant spike in raw materials as we speak, right? This has been prevalent for the last 8 to 10 weeks, from the beginning middle of March. So, it depends on how soon there will be normalized conditions because these large raw material spikes are primarily attributed to manufacturers in Asia and not so much to manufacturers in the U.S. Although U.S. manufacturers are feeling the heat of inflation as we speak, but the sourcing of raw material prices, which is a primary component in manufacturing our products has not been affected in the U.S. as compared to in India, where you see raw material price increases as much as 70% from normalized levels. So, this makes us slightly non-competitive in international markets. And of course, we will find ways on how we can maintain pricing and move ahead. But we would need better conditions for uninterrupted growth and stronger growth in international market. Every time a crisis ends, there's something huge comes up globally at this point of time over the last few years.

  10. Question

    Jasdeep Walia: Got it. Just surprising to know that raw material prices for a labware manufacturer in U.S. will be lower than you in dollar terms. I would presume both of you would buy it from the same source, right? So, RM price in dollar terms should be the same for both of you.

    Answer, aryan sehgal

    Aryan Sehgal: Most of the raw material prices are impacted from vendors across the Middle East and Asia. And a lot of raw material suppliers based in the U.S. supplying to U.S. manufacturers, the price impact hasn't been as strong as what it has been here in towards Asia, towards China, India, manufacturers have been impacted much more severely as compared to the U.S. and Europe. However, inflation is a big problem in the U.S. at this point in time, and we see cost pressures, but that's not raw material linked.

Show 16 more questions
  1. Question

    Jasdeep Walia: Got it. how do you see Chinese competition in your main export market of U.S. and Europe? Has it increased further in the last year or the competitive conditions are more benign going forward versus what you've seen in the past? Page 9 of 19 Tarsons Products Limited May 25, 2026 Aryan Sehgal: The competition has always been strong.

    Answer, aryan sehgal

    It subdued us slightly with higher tariffs, but I think with the tariffs not remaining in effect completely like the way it was. Chinese competition is fierce, both in the U.S. as well as Europe as well as other parts of the world, including Asia, Latin America and so on. The Chinese make very high-quality products. They are very, very strong in deliveries in capacity build-ups and scale-ups. They are very, very professional. And they have been in the international markets at least a decade or 1.5 decades earlier than any other Indian manufacturer. So, they always have that 15-year runway or 15-year lead over any Indian manufacturer brand in our industry, which is laboratory consumables.

  2. Question

    Jasdeep Walia: And are there additional duties on Chinese products in U.S. and Europe or they are the same for India and China?

    Answer, aryan sehgal

    Aryan Sehgal: I think in the U.S., it's very similar now, the duties between Chinese and Indian products. There's a slight difference. But in Europe, we had similar duties, but with the India, EU FTA trade deal, if it comes into effect, it is not yet into effect, we might have a benefit of about certain percentage points between us and the Chinese. Jasdeep Walia: Got it. Sometime back when I asked you the same question, you in the sense, this was 1 or 2 years back, you didn't consider Chinese as credible competition in U.S. and Europe because you used to say that U.S. brands, they don't want Chinese sourcing. That doesn't seem to be the case as of now. It seems like China has overcome.

    Answer, aryan sehgal

    Aryan Sehgal: India exports approximately INR250 crores to INR275 crores of laboratory consumables into the U.S. between all companies, including Tarsons, just in the lab consumable space. China would export more than INR275 crores a month into the U.S., and that is historically over the last 20 years. This is not an overnight phenomenon. I think you are confusing the questions what you have asked me. What you asked me was how strong is Chinese in India because of our strong reputation and brand image in India and very, very competitive prices and the import structure into India. Chinese have a very limited and small presence inside the Indian market, but the Chinese are very, very strong globally.

    Answer, aryan sehgal

    Aryan Sehgal: See, there has been a certain rationalization in competition for sure over the last 2 to 3 years, but that is more on the player in the importer level, right? There was a lot of influx of products from Page 10 of 19 Tarsons Products Limited May 25, 2026 Asia and other parts during COVID because of not enough capacities available in India to service customers. So once those capacities came in and the industry normalized, those products are not needed anymore, but there was a large inventory in the system. And that inventory needed time because the market was not big enough. So, it could not be cleared immediately, right? So, what we are seeing is not so much of a rationalization of competition, but more clearing out of inventory, which would not be reordered again. So that is what we are seeing mainly along with more and more investments in the private sector, which is leading to better demand and most of the major companies in India are well positioned to cater to that demand.

    Answer, aryan sehgal

    Aryan Sehgal: Just like how you mentioned, right, the rupee is depreciating significantly, and it has significantly depreciated over the last 6, 7 months. So , it becomes more and more complicated and expensive for companies to import and bring the product into India. The geopolitical situation is causing a lot of problems in the transport routes as well as the freight costs have gone up significantly as well. So that adds to the cost. So , all these things always play favorably to make in India producers, not only Tarsons, but anybody else who produces in India because for us, the only component which is being imported where we are paying the higher price for the rupee depreciation is the raw material. Rest of the other components which are added to the cost are all local. Aditya: Understood.

    Answer, aryan sehgal

    Aryan Sehgal: So, we are looking to gradually increase pricing because at 60% or 70% raw material price hikes, it is a large cost increase, and we would not be able to support such a large cost increase by absorbing it. However, we may not be in a position to be able to pass on the entire cost increase to our customers. And some part of that cost might have to be shared in the short term because we don't expect this to be a permanent situation where the prices remain like this over the next couple of months or years. Maybe the prices will not get back to the old levels, but there would definitely be some rationalization. Aditya: Sir, any particular reason you still not increase the price because as you mentioned, some part of the competition is affected and demand is also improving. So, doesn't it make sense for us to increase prices now? Page 11 of 19 Tarsons Products Limited May 25, 2026 Aryan Sehgal: As I said, we've gradually started increasing prices.

    Answer, aryan sehgal

    And we have to play you know we have to be very, very careful about the price increases because everybody understands that it is a temporary price increase and not a permanent price increase. So, distributors would also be very uncautious, right, of having large amounts of inventory because if the prices drop the next month, they would have a lot of inventory at higher prices as well. I'm talking about domestic distributors. So, we have gradually started in this fiscal year, which is April. And we are looking at it from a product-by-product basis and seeing rather than from an entire price list point of view.

  3. Question

    Nikhil Upadhyay: So, on markets beyond U.S. because of tariffs, I think some of our plants, and as you mentioned, even today, U.S., we are not as competitive. But market beyond U.S., what are we doing? And how do you see opportunities playing out there?

    Answer, aryan sehgal

    Aryan Sehgal: So, our focus has always been the U.S. and Europe, and we look at growing our presence in these countries while we are looking to strengthen ourselves in Asia and Latin America. So, I think we will look at good growth coming in from Asia as well as Latin America over the next 2 to 3 years. But a significant portion of our business will still keep coming from the U.S. and Europe. Nikhil Upadhyay: Okay. And one question, continuing with Aditya's question on pricing. My question is more on supply that in this period of last March to April and May, when we are talking to other companies, many companies have talked about that price has increased, but supply was a challenge, which becomes a bigger problem for smaller players. Is a similar situation applicable in your industry?

    Answer, aryan sehgal

    Aryan Sehgal: We generally compete against larger players than us very few companies we compete with, which are smaller than us. The supply is an issue. And the problem is not only the price increase but the availability. And we just have to have higher levels of inventory, stock up more and strengthen our supply chain systems to be able to navigate through this crisis. But raw material availability is a reality at this point of time, raw material supply issues, and it's throughout the industry.

  4. Question

    Nikhil Upadhyay: But during the similar period in COVID, we got a significant benefit in terms of higher growth. Would you say such a scenario can play out for us in today's market?

    Answer, aryan sehgal

    Aryan Sehgal: It cannot play out because COVID, the problem was in COVID, the customers' demand had gone significantly higher than normal, which is not the case today, right? The demand levels are good, but they are not significantly higher or unprecedentedly high, right? So, we cannot expect a situation like COVID today.

  5. Question

    Nikhil Upadhyay: But supply is constrained.

    Answer, aryan sehgal

    Aryan Sehgal: Supply is constrained, but demand is not like the way it was in COVID. There is no comparison between COVID demand and today's demand. COVID facilities, how much we produce was not enough.

  6. Question

    Nikhil Upadhyay: Okay. And last question. You mentioned now capex is largely out of window, like it would be more maintenance, INR20 crores, INR30 crores. Would you say over next 2 years, a larger part of the free cash generation would be to deleverage? And what's your idea over next 2, 3 years? What is the kind of debt we want to keep on our book?

    Answer, aryan sehgal

    Aryan Sehgal: See, we would definitely it would be to deleverage, reduce the debt on our books and I would ideally in a situation -- in an ideal situation, not want debt to increase more than 2x our EBITDA. And unless we if some significant opportunity comes up and if the markets are favorable, we might look to raise money if the debt is still significantly high in our books. But at this point in time, the focus over the next 2 to 3 years is to significantly ramp up our capacity, grow our scale and be able to earn larger cash profits to be able to deleverage, as you said.

    Answer, aryan sehgal

    See, the thing is, at the end of the day, we have to have certain rationality when it comes to pricing to be able to maintain certain cost structures when we are moving forward because if we are not being able to price our products correctly and the business significantly scales up, it's very difficult for us to reprice moving forward, especially in international markets where customers are aware that the currency depreciates as well, right? The rupee depreciates against the dollar. So most of the times, we have pressures from our buyers in the U.S. because they are well aware of where the currency has depreciated over the last 10 or 15 years, the Indian currency, but not having complete information and understanding about the inflationary pressures in India and what sort of price increments or cost increments the company faces year-over-year, which is not similar to a standard scenario in the U.S. or in Europe. So, while a 60%, 70% increase in material margin might just affect our gross margin by from 70%, it might take it to 58% or 57% and might look healthy, it may not be sustainable in the long term.

  7. Question

    Madhur Rathi: Right. Now sir, if I look at all the capex has been done. So, going forward, how should I look at our growth from the domestic market as well as from the export ODM market? So how has been the new customer addition strategy for our export business? As well as in domestic market, how if you could help us understand how has been new product launches? And how do we see the capacity ramp up? You mentioned that from FY'28, cell culture will improve materially. But if I were to consider in terms of numbers, how should I look at these maybe over the next 1 or 2 years?

    Answer, aryan sehgal

    Aryan Sehgal: Right. So, what we expect is we expect good growth from the domestic market, strong stable growth from the domestic market over the next 2 to 3 years, primarily because of our position and our base in the domestic market. We already have a very strong base. And so we should have good stable growth moving forward. And internationally, I think the growth numbers could be much higher, significantly higher than domestic the growth percentages because although the base is lower than international domestic market, but still, I think the quantum of opportunity is much higher internationally. And so we could -- depending on geopolitical situations, economic tariff situations and everything being in order being in place, the speed at which we could convert contracts, the growth may not be very homogeneous over the next 3, 4 years, but there could be some strong years of growth when we win contracts and win ODM businesses.

  8. Question

    Madhur Rathi: So, nothing material as of now that we have since commissioning these new facilities?

    Answer, santosh agarwal

    Santosh Agarwal: See, it's a normal part of business, but I don't see that INR14 crores has been increased in the traded goods because total purchase for the year is about to be INR15 crores to INR20 crores. It cannot be INR14 crores increase. I think INR1.4 million is there, and you have made it INR14 crores. Rushil: Okay. Sorry. And the second question is, since I've been saying that if we see our inventory from last 1 to 2 years and in line with our revenue. So just wanted to understand that it was something like that the raw material prices were increasing and we were not able to pass on the price and somewhere we had to take out the inventory written down also.

    Answer, santosh agarwal

    Santosh Agarwal: We are not writing off any kind of inventory. We do the provisioning on the basis of aging, but all the inventory are good inventory. If I would have to raw material inventory has been increased. And the reason was very clear. We already explained that because of supply chain disruption all over the globe, we have to keep more raw material because supply is an issue and the longterm prices also keep on increasing. But if you see the finished good, finished goods has been from INR40 crores to INR30 crores. Rushil: Okay.

    Answer, aryan sehgal

    Aryan Sehgal: No, I think raw material rates are very crude linked rates, and these are fixed spot rates. So, if the kind of the amount of volume what we do in our business, we are considered for the raw material supplier very, very small players. So, we are not in industrial plastics where we have a turnover of INR5,000, INR6,000 crores, INR7,000 crores and a gross margin of 30%, where there is 70% raw material consumption, we are buying thousands of crores of raw material and that also 1 or 2 grades. Page 15 of 19 Tarsons Products Limited May 25, 2026 Here, we are buying 20, 30, 40 different grades across different polypropylene, HDP, polycarbonate, polystyrene and we have a purchase of about INR70 crores, INR80 crores worth of raw material, which for the raw materials and spread across different vendors in the Middle East and Europe. So, for any particular raw material supplier supplying to Tarsons worth INR6 crores, INR7 crores or INR8 crores of raw material a year is nothing significant or nothing material. As a company to investors into the market, we may look like a sizable company. But in the raw material world, we are just one of the small players.

    Answer, santosh agarwal

    Santosh Agarwal: It's on a standalone level at a consol level, only Nerbe got included and Nerbe has no major depreciation, except some intangibles are there.

  9. Question

    Vibhor Talreja: Okay. So, when I do the math, I was coming to a much higher number because your Q4 depreciation itself is INR29 crores -- and you have capitalized some of the assets on March 31, I assume. And we have another INR150 crores of CWIP there, which you said you will capitalize over the next 3 to 9 months. And you mentioned the rates. So, when I do the math, the depreciation comes out to be more like INR130 crores to INR140 crores. Am I really missing something?

    Answer, santosh agarwal

    Santosh Agarwal: So, if you are calculating on a consol level, then it includes the this year depreciation is about to be INR85 crores to INR89 crores and another INR25 crores, INR30 crores depreciation will also come in the next year. So, it will come to about INR110 crores, right. Plus, some intangible depreciation and amortization will also happen at a consol level.

  10. Question

    Vibhor Talreja: Okay. So can you please once again answer what is your expected consolidated depreciation for FY'27.

    Answer, santosh agarwal

    Santosh Agarwal: At this moment, I can only give the stand-alone depreciation only because consol depreciation depends on what kind of amortization will happen at a consol level. But at a stand-alone level, I can give you a forecasted depreciation of about INR110 crores.

  11. Question

    Vibhor Talreja: Okay. Fair enough. My last question. The reason I was asking was because when I do the math and the business rightly should be valued on cash PAT and EBITDA, but it looks like on an accounting basis, we are going to have losses because the depreciation increase is here for real and the sales increase beyond the normal is some time away. Is it fair to assume that there is accounting losses expected in the expected quarters? Page 16 of 19 Tarsons Products Limited May 25, 2026 Santosh Agarwal: No, Sir, we don't expect accounting losses will be there.

    Answer, santosh agarwal

    Of course, we expect PAT to be in the range of single-digit number, but it will not be losses so far, the way things are going on because we are making EBITDA of about to be 33%, 34% and then PBT is also 9% to 10% PBT is there and then 4% to 5% of PAT is also there. And we are following written down value method. So, the depreciation will not repeat at a standalone level more than INR110 crores.

  12. Question

    Vibhor Talreja: Okay. No, the question was, our Q1 margins going to be worse than Q4 given the raw material prices have increased?

    Answer, aryan sehgal

    Aryan Sehgal: It shouldn't be worse, but should be in similar regions.

    Answer, santosh agarwal

    Santosh Agarwal: It is difficult to give you the exact guidance, but we believe that the margin should not go below 65%. Currently, in Q4, we have shown 68% kind of gross margin, but we are gradually increasing the prices also. So, it is very tough to say what kind of margin will come, but it should not go below 65%.

  13. Question

    Raman KV: Correct. So are you planning some of the factory to improve efficiency so that your gross margins will pick up? Or can we expect going forward, your gross margin levels to be at the current levels?

    Answer, aryan sehgal

    Aryan Sehgal: See, the thing is we are still not sure about how long this price increase is going to last because the way we work in India is we work on price lists, which are circulated to distributors and printed and sent to customers all across India. So, this is a situation which we never experienced before. And hence, we cannot keep altering and changing and printing new price books every 2 Page 17 of 19 Tarsons Products Limited May 25, 2026 months or 3 months because we lose credibility as well as distributors are unable to stock correctly. So hence, we are still in a wait-and-watch mode, and we are increasing as and when all the product lines based on how the raw materials have increased and what we can achieve from the customer. But it's very difficult at this point in time to give a very clear answer because we produce thousands of these price books and supply it all over the country to distributors and customers alike and we can't keep changing that every quarter. It's generally a yearly process.

  14. Question

    Raman KV: Pass through -- pass on the entire raw material prices to our customers.

    Answer, aryan sehgal

    Aryan Sehgal: There's so much of inventory in the system that are import, there are MNCs, which have stocks, which they're importing stocks. Any price increase, which is not standard, which would translate to 30%, 40% price increase price over price gives a very strong opportunity for other players to enter other players to take advantage of it. It's not a kind of industry where we could be able to take a significant price increase. However, if this becomes a permanent phenomenon and is valid to everybody, then over a medium term or short to medium term, we will see gradual changes in everybody's pricing. But if there is a short-term phenomenon spread over 3 or 4 months, there are enough players in the industry which are willing to absorb the same to be able to gain market share.

  15. Question

    Raman KV: Okay. Sir, my last question is with respect to your bioprocessing containers and cell culture. Has the production of cell culture started? And how is the ramp-up with respect to bioprocess containers going?

    Answer, aryan sehgal

    Aryan Sehgal: Yes. The ramp-up is going well for the bioprocess containers, what we are producing the bottles. And in cell culture, there are a few lines in which we've started pilot production and a few lines where we'll be starting pilot production in this quarter. So hopefully, in the next 2 or 3 months, we should have all our lines up and ready and producing and supplying samples.

  16. Question

    Raman KV: So, can we expect both of this to scale well in the second half given that the first half will be for your raw material?

    Answer, aryan sehgal

    Aryan Sehgal: I said earlier, this year, we would be able to try and get into most of the customer accounts and be able to validate our product and become one of their vendors and try to build the repeatability and reliability what they expect from us. And years starting from year 2, I think we would start seeing some improvements and then scale up every year, there would be significant scale up till probably year 4 or 5 where we reach certain amount of stability where there would be stable growth moving forward for these lines. Page 18 of 19 Tarsons Products Limited May 25, 2026 Moderator: Thank you.

Questions about this call

When was the Tarsons Products Q4 FY26 earnings call transcript filed?
Tarsons Products filed the transcript with the exchange on 1 Jun 2026. This page is built from that transcript.
What does this page list?
73 statements from the transcript across 8 topics, 44 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 26 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Tarsons Products Q4 FY26 concall: Tarsons expects improved operating leverage from ramping up its new facilities to aid operational performance from FY'27 · DalalOS